Rice Hall James & Associates LLC boosted its position in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 4.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 964,797 shares of the company’s stock after buying an additional 44,906 shares during the period. Rice Hall James & Associates LLC’s holdings in Progenics Pharmaceuticals were worth $4,071,000 at the end of the most recent quarter.

Separately, A.R.T. Advisors LLC increased its stake in shares of Progenics Pharmaceuticals by 241.6% in the first quarter. A.R.T. Advisors LLC now owns 307,523 shares of the company’s stock worth $1,340,000 after buying an additional 217,500 shares in the last quarter. Hedge funds and other institutional investors own 84.22% of the company’s stock.

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) traded down 0.84% during trading on Thursday, reaching $7.06. 1,236,782 shares of the company’s stock traded hands. The company’s market capitalization is $494.09 million. Progenics Pharmaceuticals Inc. has a 1-year low of $3.61 and a 1-year high of $8.37. The stock has a 50-day moving average of $6.36 and a 200-day moving average of $5.40.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The business earned $8.50 million during the quarter, compared to analyst estimates of $6.33 million. Progenics Pharmaceuticals had a negative net margin of 203.56% and a negative return on equity of 41.76%. The company’s revenue was up 337.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.17) earnings per share. On average, equities analysts predict that Progenics Pharmaceuticals Inc. will post $0.13 EPS for the current fiscal year.

A number of analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating on shares of Progenics Pharmaceuticals in a report on Tuesday. Brean Capital started coverage on shares of Progenics Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $11.00 price objective for the company. Zacks Investment Research cut shares of Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 27th. BTIG Research reaffirmed a “buy” rating and set a $9.00 price objective on shares of Progenics Pharmaceuticals in a research report on Wednesday, July 20th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Progenics Pharmaceuticals in a research report on Friday, June 10th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $9.35.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

5 Day Chart for NASDAQ:PGNX

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.